European Lung Cancer Congress 2024

Maximilian Diehn

Incorporating ctDNA into clinical trial design

ctDNA offers immense possibilities for improving the management of early-stage lung cancer and the area is primed for new trials to test this approach in the context of minimal residual disease

By Maximilian Diehn
Editorial_Lung

Europe cannot afford to wait any longer for cleaner air

Despite recent progress, lung cancer remains deadly and difficult to treat — and preventable, to a much greater extent with the right actions to improve the quality of the air we breathe 

    By
  • Andrés Cervantes, ESMO President

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.